Micafungine Hikma (Micafungin)

Micafungin is an echinocandin antifungal used to manage serious Candida infections.

• Invasive candidiasis: clears bloodstream and deep‑tissue Candida infection.
• Esophageal candidiasis: resolves mucosal fungal infection of the esophagus.
• Candida peritonitis: treats abdominal cavity infection caused by Candida species.
• Candida bloodstream infections: eliminates fungemia and prevents dissemination.

• Micafungin inhibits the synthesis of β‑(1,3)‑D‑glucan, an essential component of the fungal cell wall. By blocking this enzyme, the drug weakens the cell wall, leading to osmotic instability and cell lysis, which results in the selective killing of susceptible Candida species while sparing human cells.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Fever: transient temperature rise during infusion.
• Nausea: mild gastrointestinal upset.
• Headache: occasional mild to moderate pain.
• Infusion‑related reactions: flushing, chills, or erythema.
• Elevated liver enzymes: mild transaminase increase.
• Rash: mild skin irritation or erythema.

Serious or Rare Side Effects

• Severe hepatic failure: marked elevation of liver enzymes or jaundice.
• Anaphylaxis: acute, life‑threatening allergic reaction.
• Severe hypersensitivity: including angioedema.
• Renal failure: acute kidney injury in predisposed patients.
• Stevens‑Johnson syndrome: severe skin and mucosal involvement.
• Cardiac arrhythmia: rare conduction disturbances.

When using Micafungine Hikma, clinicians should observe several safety measures.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic impairment: assess liver enzymes before and during treatment.
• Pregnancy: risk unknown; use only if potential benefit justifies the risk.
• Concomitant immunosuppressants: monitor drug levels and possible toxicity.
• Hypersensitivity: discontinue if signs of allergic reaction appear.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce micafungin exposure.
• Duplicate echinocandin therapy: increases risk of toxicity without added benefit.
• Known hypersensitivity to micafungin or any component: may trigger severe allergic reaction.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole): can raise micafungin plasma levels.
• Immunosuppressants (e.g., tacrolimus, cyclosporine): may require dose adjustment.
• Nephrotoxic agents (e.g., aminoglycosides): increase risk of renal injury.
• Concomitant use with warfarin: monitor coagulation parameters.